

1 **Seroprevalence of SARS-CoV-2 Antibodies Among 925 Staff Members in an**
2 **Urban Hospital Accepting COVID-19 Patients in Osaka Prefecture, Japan**

3

4 Tsuotmu Nishida¹⁾, Hiromi Iwahashi^{2) 3)}, Kazuhiro Yamauchi⁴⁾, Noriko Kinoshita⁴⁾,
5 Yuki Yoshi Okauchi^{2) 3)}, Norihiro Suzuki⁵⁾, Masami Inada¹⁾, Kinya Abe^{2) 5)}

6

7 **Affiliations:**

8 1) Department of Gastroenterology, Toyonaka Municipal Hospital

9 2) Department of Internal Medicine, Toyonaka Municipal Hospital

10 3) Diabetes Center, Toyonaka Municipal Hospital

11 4) Division of Clinical Laboratory, Toyonaka Municipal Hospital

12 5) Infection Control Office, Toyonaka Municipal Hospital

13

14 **Running Head:** Seroprevalence of SARS-CoV-2 at Hospital in Japan

15

16 **Word count:** 2317

17

- 18 Address all correspondence: Tsutomu Nishida, M.D. Ph.D.
- 19 Department of Gastroenterology, Toyonaka Municipal Hospital
- 20 4-14-1 Shibahara, Toyonaka, Osaka 560-8565 Japan
- 21 E-mail: tnishida.gastro@gmail.com
- 22 Tel: +81-6-6843-0101
- 23 Fax: +81-6-6858-3531

24 **Abstract**

25 **Background:** The subclinical severe acute respiratory syndrome coronavirus 2
26 (SARS-CoV-2) infection rate in hospitals during the pandemic remains unclear. To
27 evaluate the effectiveness of our hospital's current nosocomial infection control, we
28 conducted a serological survey of the anti-SARS-CoV-2 antibody (immunoglobulin G)
29 among the staff of our hospital, which is treating coronavirus disease 2019 (COVID-19)
30 patients.

31 **Methods :** The study design was cross-sectional. We measured anti-SARS-CoV-2
32 immunoglobulin G in the participants using a laboratory-based quantitative test (Abbott
33 immunoassay), which has a sensitivity and specificity of 100% and 99.6%, respectively.
34 To investigate the factors associated with seropositivity, we also obtained some
35 information from the participants with an anonymous questionnaire.

36 **Results:** We invited 1133 staff members in our hospital, and 925 (82%) participated.
37 The mean age of the participants was 40.0 ± 11.8 years, and most were women (80.0%).
38 According to job title, there were 149 medical doctors or dentists (16.0%), 489 nurses
39 (52.9%), 140 medical technologists (14.2%), 49 healthcare providers (5.3%), and 98

40 administrative staff (10.5%). The overall prevalence of seropositivity for
41 anti-SARS-CoV-2 IgG was 0.43% (4/925), which was similar to the control
42 seroprevalence of 0.54% (16/2970)) in the general population in Osaka during the same
43 period according to a government survey conducted with the same assay. Seropositive
44 rates did not significantly differ according to job title, exposure to suspected or
45 confirmed COVID-19 patients, or any other investigated factors.

46 **Conclusion:** The subclinical SARS-CoV-2 infection rate in our hospital was not higher
47 than that in the general population under our nosocomial infection control measures.

48

49 **Keywords**

50 Severe acute respiratory syndrome coronavirus 2, COVID-19, Seroprevalence, Hospital
51 staff, Nosocomial infection

52

53 **Introduction**

54 Coronavirus disease (COVID-19), which is caused by infection with severe
55 acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first appeared in Wuhan,
56 China, in December 2019 and triggered a pandemic. Since COVID-19 emerged, an
57 increasing number of people have contracted it and died around the world. Hospital
58 staff are at the front line of the efforts to control the ongoing COVID-19 pandemic and
59 are at high risk of infection with SARS-CoV-2, which is highly contagious.
60 Consequently, nosocomial SARS-CoV-2 infections in hospital staff can be problematic.
61 Chu et al. reported that this disease is often diagnosed in medical staff who were not in
62 charge of affected patients in a hot spot region of the pandemic ¹.

63 As of July 14, 2020, a total of 12,964,809 people had been infected with
64 SARS-CoV-2, and 570,288 people had died of COVID-19 worldwide, with a total of
65 22,220 confirmed cases and 980 deaths in Japan according to the World Health
66 Organization (WHO) Situation Report -176 ². Compared with the global situation, Japan
67 has achieved relatively better control of the pandemic and has maintained a relatively
68 low incidence of nosocomial infections in the hospital. However, there are few available
69 data on the rate of seropositivity for SARS-CoV-2 antibodies in hospital staff in Japan.

70 Our hospital is a medium-volume hospital with 613 beds, including 14 in the Infectious
71 Disease Unit. It is in an urban area of Osaka Prefecture, Japan, and is a designated
72 medical institution for type II infectious diseases. There are 351 medical institutions
73 with 1,758 beds in Japan. At the same time, as one of the region's essential hospitals,
74 our hospital plays a significant role in community care. At the government's request, we
75 were the hospital to accept four asymptomatic COVID-19 patients from the cruise ship,
76 the Diamond Princess, on February 22, 2020. After that, COVID-19 spread in Japan,
77 and the number of patients admitted to our hospital gradually increased. Due to the
78 pandemic, Osaka Prefecture requested an increase in the availability of beds for
79 COVID-19 patients. Finally, we expanded our capacity to 45 beds for patients with
80 COVID-19. The Infectious Disease Ward in our hospital is mainly staffed by physicians
81 on a weekly rotation and nurses on a one- or two-month rotation. In addition, we have
82 provided specific medical care for outpatients with fevers since March 2020. We have
83 implemented basic hospital infection control measures to prevent the spread of
84 COVID-19 according to the manuals (in Japanese) produced by the Japanese Society
85 for Infection Prevention and Control ³ and the National Center for Global Health and

86 Medicine ⁴. In brief, we have implemented standard precautions for general patients and
87 have used personal protective equipment (PPE), including N95 masks, face shields,
88 caps, gowns and double gloves, when treating patients with suspected or confirmed
89 COVID-19. We occasionally had a shortage of PPE, which we addressed by using
90 alternative PPE ⁵. Administrative staff also helped medical staff and used the PPE
91 described above when they came into contact with patients with suspected COVID-19.

92 To evaluate the effectiveness of our hospital's current countermeasures against
93 nosocomial infections in the context of the COVID-19 pandemic, we investigated the
94 subclinical SARS-CoV-2 infection rate in staff at our hospital by measuring
95 anti-SARS-CoV-2 IgG and identified the risk factors for infection at our hospital, which
96 is accepting COVID-19 patients during the pandemic in Japan.

97

98 **Methods**

99 **Study participants, sample size and setting**

100 This was a cross-sectional study to examine the prevalence of anti-SARS-CoV-2
101 immunoglobulin (Ig) G. The study subjects consisted of 1133 hospital staff in 810
102 full-time jobs and 323 part-time jobs at Toyonaka Municipal Hospital. They underwent
103 an annual regular health check-up in Japan from June 12 to 19, 2020. We investigated
104 the prevalence of anti-SARS-CoV-2 IgG and the risk factors for seropositivity in those
105 who had and did not have direct contact with patients with confirmed or suspected cases
106 of COVID-19.

107 We invited all our hospital staff planning to undergo a regular health check-up to
108 participate in this study via the intranet at our hospital. The following individuals were
109 excluded from the study: those who refused to take part in this study; those who did not
110 have enough extra blood drawn to undergo antibody testing; and those who were not
111 identified because they mistyped their personal ten-digit identification code. Finally, in
112 925 participants, we measured antibodies in extra serum from blood samples taken
113 during the regular health check-up.

114 To investigate the risk factors for seropositivity, we asked participants to answer
115 an anonymous questionnaire consisting of 14 questions about their background, their
116 involvement with general patients, their involvement with patients with suspected or
117 confirmed cases of COVID-19, and their general condition via the Web using a Google
118 form. The details of this questionnaire are shown in Table 1.

119 The present study was conducted in accordance with the principles of the
120 Declaration of Helsinki, and approval was obtained from the Institutional Review Board
121 of Toyonaka Municipal Hospital (No. 2020-05-08). We obtained written informed
122 consent from participants prior to the study.

123

124 **Sample**

125 All samples were collected and stored at -20°C until use. IgG antibodies against
126 SARS-CoV-2 were detected using a laboratory-based quantitative assay (Abbott
127 ARCHITECT[®] SARS-CoV-2 IgG Assay; chemiluminescence microparticle
128 immunoassay; sensitivity: 100%, specificity: 99.6%; Abbott Laboratories, IL, USA)
129 performed on the Abbott Architect i4000SR (Abbott Diagnostics, IL, USA) at the

130 Division of Clinical Laboratory in our hospital according to the manufacturer's
131 instructions. The Food and Drug Administration (FDA) has not fully authorized any
132 COVID-19 test, but this kit has been authorized for emergency use ⁶.

133

134 **Outcomes**

135 The primary outcome was the rate of seropositivity for anti-SARS-CoV-2 IgG.
136 The key secondary outcomes were the rate of seropositivity for anti-SARS-CoV-2 IgG
137 stratified by job title, work tasks, direct contact with general patients, direct contact with
138 patients with suspected or confirmed cases of COVID-19, a history of cold-like
139 symptoms from February to June 2020, commuting methods, and number of
140 cohabitants.

141

142 **Statistical analysis**

143 The means \pm standard deviations are reported for continuous variables.
144 Categorical variables are summarized as frequencies (percentages) with 95% confidence
145 intervals (CIs) for the rate of seropositivity. A t-test was used to compare age.

146 Differences were assessed by Fisher's exact test or the chi-square test. All reported P
147 values were two-sided, and $P < 0.05$ was considered significant. The statistical analyses
148 were performed with JMP statistical software (ver. 14.3, SAS Institute, Inc., Cary, NC,
149 USA).
150

151 **Results**

152 Of the 1133 hospital staff who had planned to undergo an annual health check-up
153 at our hospital in June 2020, 926 agreed to participate in the present study. Finally, 925
154 (81.6%) were tested for anti-SARS-CoV-2 IgG. One person was not tested due to an
155 inadequate amount of serum. There was a female predominance (80.0%). The mean age
156 was 40.0 ± 11.8 years. There were 149 medical doctors or dentists (16.0%), 489 nurses
157 (52.9%), 140 medical technologists (14.2%), 49 healthcare providers (5.3%), and 98
158 administrative staff members (10.5%) (Table 2).

159 Overall, 4 participants were positive for anti-SARS-CoV-2 IgG (0.43%, 95%
160 confidential interval (CI); 0.17-1.1%). Seropositive participants were significantly older
161 than seronegative participants (52.8 ± 6.8 vs. 40.0 ± 11.8 , $P=0.0309$), but sex was not
162 significantly different (males: 50% (2/4) vs. 19.9% (183/921), $P=0.1805$). Table 2
163 shows the prevalence of seropositivity for anti-SARS-CoV-2 IgG stratified by the
164 participants' characteristics. Doctors and dentists had a slightly higher rate of
165 seropositivity (1.3%) than people in other jobs, but there was no significant difference
166 in rates among people with different job titles. No hospital staff responded that they had

167 been diagnosed with COVID-19 since February 2020.

168 Table 3 shows the prevalence of seropositivity for anti-SARS-CoV-2 IgG based

169 on exposure to patients with COVID-19. Subjects who had experienced common cold

170 symptoms from February 2020 to June 2020 had a slightly higher seropositivity rate,

171 but the difference was not significant. There were no significant differences in rates

172 based on any other factors.

173

174 **Discussion**

175 During the three months from February 22 to May 31, our hospital accepted 75
176 patients with confirmed COVID-19⁷. We also performed a total of 415 nasopharyngeal
177 swabs for the detection of SARS-CoV-2 during this period, and 61 were positive
178 (14.7%) (data not shown). We have implemented standard precautions when caring for
179 general patients and have used PPE when caring for patients with suspected or
180 confirmed cases of COVID-19. Under the current circumstances, it is important to
181 investigate the subclinical SARS-CoV-2 infection rate in our staff and to evaluate the
182 effectiveness of our nosocomial infection control measures.

183 This study showed that the prevalence of seropositivity for SARS-CoV-2 IgG as
184 evaluated with a laboratory-based quantitative test (Abbott immunoassay) was 0.43% in
185 our hospital. Considering that the sensitivity of this assay is 100%, the true-positive rate
186 in our hospital should be less than 0.43%. In addition, 0.43% is similar to or less than
187 the proportion (0.54% (16/2970)) identified by the same assay in the general population
188 in Osaka during the same period (7). The results of this study demonstrated that our
189 nosocomial infection control measures have thus far been successful.

190 Until now, the percentage of the staff of a general hospital with subclinical
191 SARS-CoV-2 infections has remained unclear. Although it may change according to the
192 epidemic condition in the region in which the hospital is located or the number of
193 COVID-19 patients the hospital accepted, this percentage is an important metric for the
194 evaluation of the effectiveness of the nosocomial infection control measures
195 implemented by the hospital. Our hospital is located in the pandemic region in Japan,
196 however, the situation regarding the pandemic is much more severe in China than in
197 Japan ⁸. The strength of the present study was that we could compare the results with
198 large-scale control data in the same region. Osaka is the second-largest metropolitan
199 region in Japan, with a population of 2.67 million. As of July 21, 2020, there was a total
200 of 2541 confirmed cases COVID-19 and 84 related deaths in the Osaka region.
201 Fortunately, the Ministry of Health, Labour and Welfare of Japan conducted a
202 seroprevalence survey in the general population in three different regions in Japan,
203 including Osaka, during the same period and using the same immunoassay from Abbott
204 Laboratories, which revealed seropositive rates of 0.54% (16/2970) in Osaka, 0.2%
205 (4/1971) in Tokyo, and 0.11% (3/3009) in Miyagi ⁹. Therefore, we can compare this

206 seropositive rate in Osaka with our rate. Compared with the seropositive rate of 0.54%
207 in the general population in Osaka, our results indicate that we have thus far
208 successfully managed to avoid hospital-acquired infections.

209 The Softbank Group Corp. conducted a serological survey from May 12, 2020,
210 to June 8, 2020, which has been the most extensive survey in Japan, identifying 191
211 positive results in 44,066 volunteers (0.43%), including 38,216 employees at Softbank
212 Group and their family members. This positive rate was similar to our result. However,
213 they used different antibody kits manufactured by Zhejiang Orient Gene Biotech Co.,
214 Ltd. (China) and Innovita (China), which are not endorsed by the WHO. In addition, the
215 Softbank Group survey also consisted of 5850 subjects with ties to a hospital, and 105
216 were positive, for a seropositive rate of 1.79%¹⁰. They concluded that health care
217 providers are generally more likely than the general public to be positive for
218 anti-SARS-CoV-2 antibodies¹⁰. However, the positive rate of 0.43% in our hospital
219 was similar to that in the general population in Osaka. These data also suggested that
220 our infection control measures appear to have been more effective against SARS-CoV-2
221 than those of other hospitals.

222 We obtained some information about the participants' backgrounds, their
223 involvement with general patients, their involvement with patients with suspected or
224 confirmed cases of COVID-19, and their general condition. We attempted to investigate
225 risk factors associated with seropositivity, but the low positive rate made this impossible.
226 Future studies with a longer period will be needed.

227 This study has several limitations. First, we could not survey all the staff in our
228 hospital; thus, the prevalence found in this study may not be exact. However, more than
229 80% of the hospital staff in our hospital, including staff in all jobs, were involved in the
230 present study. We believe the result obtained from this study is very close to the exact
231 value. Second, there is an issue with serological tests. Serological tests do not detect the
232 virus itself and instead reflect the body's immune response to infection by the virus.
233 Therefore, false-positive results are possible due to cross-reactivity with pre-existing
234 antibodies and other reasons. The specificity of the immunoassay used in this study is
235 reported to be 99.6%, indicating that there could have been four false-positive cases in
236 every 1000 subjects tested¹¹. Although we should consider this limitation of the

237 serological test, we can assume at the very least that the subclinical SARS-CoV-2

238 infection rate is less than 0.43% in our hospital.

239 In conclusion, we found that the subclinical SARS-CoV-2 infection rate in our

240 hospital, which treats COVID-19 patients during the pandemic in Japan, is not higher

241 than that in the general population in the same area during the same period. Timely

242 serological screening of a large cohort is essential for achieving control during the

243 pandemic¹². Furthermore, hospital-based antibody screening could also help us

244 evaluate and monitor infection control. A longitudinal survey of serum antibodies

245 would be necessary to clarify whether control measures have been effective.

246

247 **Author Contributors**

248 Conceptualization; Nishida T and Iwahashi H, Data curation; Nishida T, Formal

249 analysis; Nishida T and Iwahashi H, Funding acquisition; Nishida T and Iwahashi H,

250 Investigation; Nishida T, Yamauchi K and Kinoshita N, Methodology; Nishida T and

251 Iwahashi H, Project administration; Nishida T and Iwahashi H, Resources; Yamauchi K

252 and Kinoshita N, Supervision; Iwahashi H, Roles/Writing - original draft writing

253 Nishida T, review & editing; Iwahashi H, Okauchi Y, Suzuki N, Inada M, Abe K .

254

255 **Declaration of interests**

256 We have no conflicts of interest to declare.

257

258 **Funding**

259 Unrestricted research funds from the Department of Gastroenterology and Department

260 of Internal Medicine, Diabetes Center, Toyonaka Municipal Hospital.

261

262 **Acknowledgements**

263 We thank Issuikai and Hokenkagakunishinohon for collecting and storing the serum

264 samples from our staff.

265 **Table 1.** Questionnaire collecting information on the participants' background,
266 involvement with general patients, involvement with patients with suspected or
267 confirmed cases of COVID-19, and general condition from February 2020 in a
268 multiple-choice format.
269

	Question	Answer
Q1.	Notification of the test results	Yes No, I do not wish to be informed.
Q2	Health check-up ID	10-digit number
Q3	Date of examination	Date
Q4	Sex	Male Female
Q5	Age	
Q6	Job title	Doctor/dentist Nurse Medical technologist (pharmacist, radiation technologist, clinical laboratory technologist, physical therapist, occupational therapist, clinical psychotherapist, nutritionist dietician, clinical engineer) Healthcare providers Administrative worker
Q7	Are you engaged in a job in which you have direct contact with general patients?	Yes No
Q8	If you are a physician, please tell us about your specialty and position.	(a) Specialty (b) Position: chief doctor, attending Doctor, resident
Q9	Have you ever been diagnosed with COVID-19?	Yes No
Q10	Have you have direct contacted with patients with confirmed COVID-19 in the hospital?	Yes No

Q11	Have you had contact with patients with suspected COVID-19?	Yes No
Q12	Nature of the work	
	(a) Have you ever worked in the COVID-19 ward in the hospital?	Yes No
	If yes, how long have you been involved in total?	Approximately 1 week Approximately 1 to 4 weeks Approximately 4 weeks or more
	(b) Have you ever worked with outpatients in the fever clinic to management tracing contacts with regard to COVID-19?	Yes No
	If yes, how many times have you been involved in total?	1-5 times 6-10 times 11 times or more
	(c) Have you ever performed a nasopharyngeal swab test for the detection of SARS-COV-2?	Yes No
	If yes, how many times have you performed the test in total?	1-5 times 6-10 times 11 times or more
	(d) Have you ever experienced any common cold symptoms between February 2020 and today (e.g., fever or fatigue)?	Yes No
Q13	Which of these do you use to commute to work?	Public transportation Private car Walk/bicycle
Q14	How many people, including you, do you live with?	Number

270

271

272 **Table 2.** Seropositive rate according to characteristics.

	N (%)	Seropositive N (%)	95% CI (%)	P value
Total number	925	4 (0.43)	0.17-1.1	
Sex				0.1805
Male	185 (20)	2 (1.1)	0.30-3.9	
Female	740 (80)	2 (0.27)	0.074-1.0	
Age group, years				0.5232
20-29	234 (25)	0		
30-39	225 (24)	1 (0.44)	0.079-2.5	
40-49	250 (27)	1 (0.40)	0.071-2.2	
50-69	216 (25)	2 (0.93)	0.25-3.3	
Job title				0.2809
Doctor or dentist	149	2 (1.3)	0.37-4.8	
Nurse	489	1 (0.20)	0.036-1.1	
Medical technologist	140	0 (0)		
Healthcare provider	49	0 (0)		
Administrative staff	98	1 (1.0)	0.18-5.6	
Doctor specialty*				1.000
Internist specialty	59	1 (1.7)	0.30-9.0	
Surgical specialty	85	1 (1.2)	0.21-6.4	
Doctor position				0.2467
Chief doctor	40	0 (0)		
Attending doctor	63	2 (3.2)	0.88-11	
Resident	46	0 (0)		

273 CI; confidential interval *Missing data N=5

274 **Table 3.** Seropositive rate according to work at the hospital.

Question	N (%)	Seropositive N (%)	95% CI (%)	P value
Total number	925	4 (0.43)	0.17-1.1	
Direct contact with patients				1.0000
Yes	758 (81.9)	4 (0.53)	0.21-1.3	
No	167 (18.1)	0 (0)		
Direct contact with confirmed COVID-19 patients				0.3282
Yes	267 (28.9)	2 (0.75)	0.21-2.7	
No	658 (71.1)	2 (0.30)	0.083-1.1	
Direct contact with suspected COVID-19 patients				1.000
Yes	452	2 (0.44)	0.12-1.6	
No	473	2 (0.42)	0.11-1.5	
Work experience in the ward for COVID-19 patients?				1.000
Yes	216	1 (0.46)	0.082-2.6	
No	709	3 (0.42)	0.14-1.2	
Work experience at fever outpatient clinic related to the management of contact with suspected COVID-19 patients?				1.000
Yes	145	0 (0)		
No	780	4 (0.51)	0.20-1.3	
Performance of a nasopharyngeal swab test for <i>the</i> detection of SARS-CoV-2 at fever outpatient clinic related to the management of contact with suspected COVID-19 patients?				1.000

Yes	72	0 (0)		
No	853	4 (0.47)	0.18-1.2	
Common cold symptoms				0.0716
Yes	110	2 (1.8)	0.50-6.4	
No	815	2 (0.25)	0.067-0.89	
Commute method				0.3682
Public transportation	396	3 (0.76)	0.26-2.2	
Private car	214	0 (0)		
Walk/bicycle	315	1 (0.32)	0.056-1.8	
Cohabitant number				0.0773
1	220	0 (0)		
2	204	3 (1.5)	0.50-4.2	
3	188	0 (0)		
4	207	0 (0)		
5 or more	106	1 (0.94)	0.17-5.2	

275 CI; confidence interval

276

277

278 **References**

- 279 1. Chu J, Yang N, Wei Y *et al.* Clinical characteristics of 54 medical staff with
280 COVID-19: A retrospective study in a single center in Wuhan, China. *J Med*
281 *Virol* 2020; doi 10.1002/jmv.25793.
- 282 2. WHO. Coronavirus disease (COVID-19) Situation Report – 176,
283 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/2020071](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200714-covid-19-sitrep-176.pdf?sfvrsn=d01ce263_2)
284 [4-covid-19-sitrep-176.pdf?sfvrsn=d01ce263_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200714-covid-19-sitrep-176.pdf?sfvrsn=d01ce263_2); 2020 [accessed Aug 7, 2020].
- 285 3. Japanese Society for Infection Prevention and Control
286 http://www.kankyokansen.org/modules/news/index.php?content_id=328; 2020
287 [accessed Aug 7, 2020].
- 288 4. National Center for Global Health and Medicine,
289 <https://www.ncgm.go.jp/covid19/PDF/20200616.pdf>; 2020 [accessed Aug 7,
290 2020].
- 291 5. Nishida T, Suzuki N, Ono Y *et al.* How to make an alternative plastic gown
292 during the personal protective equipment shortage due to the COVID-19
293 pandemic. *Endoscopy* 2020; doi 10.1055/a-1197-5949.

- 294 6. US Food and Drug Administration. EUA Authorized Serology Test Performance,
295 <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua>
296 [-authorized-serology-test-performance](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorized-serology-test-performance); 2020 [accessed July 19, 2020].
- 297 7. Higuchi T, Nishida T, Iwahashi H *et al.* Early Clinical Factors Predicting the
298 Development of Critical Disease in Japanese Patients with COVID-19: A
299 Single-Center Retrospective, Observational Study. *medRxiv* 2020; doi
300 10.1101/2020.07.29.20159442: 2020.07.29.20159442.
- 301 8. Chen Y, Tong X, Wang J *et al.* High SARS-CoV-2 antibody prevalence among
302 healthcare workers exposed to COVID-19 patients. *J Infect* 2020; doi
303 10.1016/j.jinf.2020.05.067.
- 304 9. Ministry of Health, Labor and Welfare of Japan
305 <https://www.mhlw.go.jp/content/000640287.pdf>; 2020 [accessed July 6, 2020].
- 306 10. Softbank Group, <https://group.softbank/system/files/pdf/antibodytest.pdf>; 2020
307 [accessed July 7].
- 308 11. Nakamura A, Sato R, Ando S *et al.* Seroprevalence of Antibodies to
309 SARS-CoV-2 in Healthcare Workers in Non-epidemic Region: A Hospital

- 310 Report in Iwate Prefecture, Japan. *medRxiv* 2020; doi
- 311 10.1101/2020.06.15.20132316; 2020.06.15.20132316.
- 312 12. Abbasi J The Promise and Peril of Antibody Testing for COVID-19. *Jama* 2020;
- 313 doi 10.1001/jama.2020.6170.
- 314